FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1799-1809 November 1, 2007 Number 18 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Calis, K. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Mortality is increased after a hip fracture, and strategies that improve outcomes are needed.

Methods In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture.

Results The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups.

Conclusions An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov] .)

Source Information

From Duke University Medical Center (K.W.L., C.S.C.-E., C.F.P., K.A.M., P.K.H.) and the Geriatrics Research Education and Clinical Center, Veterans Affairs Medical Center (K.W.L.) — both in Durham, NC; the University of Maryland, Baltimore (J.S.M.); McMaster University, Hamilton, ON, Canada (J.D.A.); Centro de Osteopatías Médicas, Buenos Aires (C.M.); Hvidovre Hospital, Hvidovre, Denmark (L.H.); United Osteoporosis Centers, Gainesville, GA (C.R.); Ullevål University Hospital, Oslo (L.N.); Novartis Pharmaceuticals, East Hanover, NJ (C.L., J.Z., P.M., K.A., J.J.O.); Savient Pharmaceuticals, East Brunswick, NJ (Z.H.); Novartis Pharma, Basel, Switzerland (E.F.E.); and Katholieke Universiteit Leuven, Leuven, Belgium (S.B.).

This article (10.1056/NEJMoa074941) was published at www.nejm.org on September 17, 2007.

Address reprint requests to Dr. Lyles at the Department of Medicine, Box 3881, Duke University Medical Center, Durham, NC 27710, or at kenneth.lyles{at}duke.edu.

Full Text of this Article

Related Letters:

Zoledronate, Fractures, and Mortality after Hip Fracture
van den Berg P., Lopez C. A., Tasneem Z., Karam R., Al-Khalidi H., Steinbuch M., Colon-Emeric C. S., Lyles K. W., Mesenbrink P., the HORIZON Recurrent Fracture Trial
Extract | Full Text | PDF  
N Engl J Med 2008; 358:967-969, Feb 28, 2008. Correspondence

This article has been cited by other articles:

• Bobyn, J. D., McKenzie, K., Karabasz, D., Krygier, J. J., Tanzer, M. (2009). Locally Delivered Bisphosphonate for Enhancement of Bone Formation and Implant Fixation. JBJS 91: 23-31 [Full Text]  
• Dell, R. M., Greene, D., Anderson, D., Williams, K. (2009). Osteoporosis Disease Management: What Every Orthopaedic Surgeon Should Know. JBJS 91: 79-86 [Full Text]  
• Sennerby, U., Melhus, H., Gedeborg, R., Byberg, L., Garmo, H., Ahlbom, A., Pedersen, N. L., Michaelsson, K. (2009). Cardiovascular Diseases and Risk of Hip Fracture. JAMA 302: 1666-1673 [Abstract] [Full Text]  
• Raj, S. R., Stein, C. M., Saavedra, P. J., Roden, D. M. (2009). Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120: 1123-1132 [Full Text]  
• Burkiewicz, J. S, Scarpace, S. L, Bruce, S. P (2009). Denosumab in Osteoporosis and Oncology. The Annals of Pharmacotherapy 43: 1445-1455 [Abstract] [Full Text]  
• BUENCAMINO, M. C. A., PALOMO, L., THACKER, H. L. (2009). How menopause affects oral health, and what we can do about it. Cleveland Clinic Journal of Medicine 76: 467-475 [Abstract] [Full Text]  
• Bliuc, D., Nguyen, N. D., Milch, V. E., Nguyen, T. V., Eisman, J. A., Center, J. R. (2009). Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women. JAMA 301: 513-521 [Abstract] [Full Text]  
• Andrews, N. A. (2009). Postoperative Management of Hip Fractures: Recent inaugural IBMS BoneKEy Online Forum focused on pharmacological and non-pharmacological approaches to managing patients post-hip fracture. IBMS BoneKEy 6: 55-62 [Full Text]  
• Hegge, K. A., Fornoff, A. S., Gutierres, S. L., Haack, S. L. (2009). New Therapies for Osteoporosis. Journal of Pharmacy Practice 22: 53-64 [Abstract]  
• Grey, A., Bolland, M. J., Wattie, D., Horne, A., Gamble, G., Reid, I. R. (2009). The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. J. Clin. Endocrinol. Metab. 94: 538-544 [Abstract] [Full Text]  
• Majumdar, S. R., Lier, D. A., Beaupre, L. A., Hanley, D. A., Maksymowych, W. P., Juby, A. G., Bell, N. R., Morrish, D. W. (2009). Osteoporosis Case Manager for Patients With Hip Fractures: Results of a Cost-effectiveness Analysis Conducted Alongside a Randomized Trial. Arch Intern Med 169: 25-31 [Abstract] [Full Text]  
• (2008). Annual {blacktriangledown}zoledronic acid for osteoporosis. DTB 46: 93-96 [Abstract] [Full Text]  
• CAREY, J. J., PALOMO, L. (2008). Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?. Cleveland Clinic Journal of Medicine 75: 871-879 [Abstract] [Full Text]  
• Cole, P. A., Miclau, T. III, Ly, T. V., Switzer, J. A., Li, M., Morgan, R. A., Bhandari, M. (2008). What's New in Orthopaedic Trauma. JBJS 90: 2804-2822 [Full Text]  
• Colon-Emeric, C. S. (2008). Fracture Prevention in Frail Older Adults: Why, When and How. IBMS BoneKEy 5: 426-435 [Abstract] [Full Text]  
• Miki, R. A., Oetgen, M. E., Kirk, J., Insogna, K. L., Lindskog, D. M. (2008). Orthopaedic Management Improves the Rate of Early Osteoporosis Treatment After Hip Fracture. A Randomized Clinical Trial. JBJS 90: 2346-2353 [Abstract] [Full Text]  
• Berenson, J. R., Yellin, O., Boccia, R. V., Flam, M., Wong, S.-F., Batuman, O., Moezi, M. M., Woytowitz, D., Duvivier, H., Nassir, Y., Swift, R. A. (2008). Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss. Clin. Cancer Res. 14: 6289-6295 [Abstract] [Full Text]  
• Qaseem, A., Snow, V., Shekelle, P., Hopkins, R. Jr., Forciea, M. A., Owens, D. K., for the Clinical Efficacy Assessment Subcommittee, (2008). Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians. ANN INTERN MED 149: 404-415 [Abstract] [Full Text]  
• Drake, M. T., Clarke, B. L., Khosla, S. (2008). Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clin Proc. 83: 1032-1045 [Abstract] [Full Text]  
• Woodis, C B. (2008). Once-Yearly Administered Intravenous Zoledronic Acid for Postmenopausal Osteoporosis. The Annals of Pharmacotherapy 42: 1085-1089 [Abstract] [Full Text]  
• Black, D. M., Boonen, S., Delmas, P., Lyles, K. W. (2008). Review of Comparative Effectiveness of Treatments to Prevent Fractures. ANN INTERN MED 148: 885-886 [Full Text]  
• Gehrig, L., Lane, J., O'Connor, M. I. (2008). Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons. JBJS 90: 1362-1374 [Full Text]  
• Cole, Z., Dennison, E., Cooper, C. (2008). Update on the treatment of post-menopausal osteoporosis. Br Med Bull 86: 129-143 [Abstract] [Full Text]  
• Parikh, S., Mogun, H., Avorn, J., Solomon, D. H. (2008). Osteoporosis Medication Use in Nursing Home Patients With Fractures in 1 US State. Arch Intern Med 168: 1111-1115 [Abstract] [Full Text]  
• Cauley, J. A., Ensrud, K. E. (2008). Considering Competing Risks . . . Not All Black and White. Arch Intern Med 168: 793-795 [Full Text]  
• Sorensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D, Cummings, S. R, Baron, J. A (2008). Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336: 813-816 [Abstract] [Full Text]  
• Majumdar, S. R (2008). Oral bisphosphonates and atrial fibrillation. BMJ 336: 784-785 [Full Text]  
• Ebeling, P. R. (2008). Osteoporosis in Men. NEJM 358: 1474-1482 [Full Text]  
• Cheung, A. M., Detsky, A. S. (2008). Osteoporosis and Fractures: Missing the Bridge?. JAMA 299: 1468-1470 [Full Text]  
• Compston, J. E. (2008). Zoledronic Acid - Does It Have Anabolic as Well as Anti-Resorptive Effects?. IBMS BoneKEy 5: 103-107 [Full Text]  
• van den Berg, P., Lopez, C. A., Tasneem, Z., Karam, R., Al-Khalidi, H., Steinbuch, M., Colon-Emeric, C. S., Lyles, K. W., Mesenbrink, P., the HORIZON Recurrent Fracture Trial, (2008). Zoledronate, fractures, and mortality after hip fracture.. NEJM 358: 967-968 [Full Text]  
• MacLaughlin, E. J., Raehl, C. L. (2008). ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. Am J Health Syst Pharm 65: 343-357 [Full Text]  
• MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., Desai, S. B., Zhou, A., Chen, S., Carter, J., Tringale, C., Valentine, D., Johnsen, B., Grossman, J. (2008). Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. ANN INTERN MED 148: 197-213 [Abstract] [Full Text]  
• Jones, G., Winzenberg, T. (2008). Cardiovascular risks of calcium supplements in women. BMJ 336: 226-227 [Full Text]  
• Reid, I. R. (2008). Pathogenesis of Osteonecrosis of the Jaw. IBMS BoneKEy 5: 69-77 [Abstract] [Full Text]  
• Tosi, L. L., Gliklich, R., Kannan, K., Koval, K. J. (2008). The American Orthopaedic Association's "Own the Bone" Initiative to Prevent Secondary Fractures. JBJS 90: 163-173 [Abstract] [Full Text]  
• Dabrera, G. (2007). Use of an integrated care pathway in improving secondary prevention of osteoporosis. Intl J Care Pathw 11: 126-127 [Full Text]  
• (2007). Protection for Those Who Have Experienced Hip Fracture. JWatch Women's Health 2007: 4-4 [Full Text]  
• Calis, K. A., Pucino, F. (2007). Zoledronic Acid and Secondary Prevention of Fractures. NEJM 357: 1861-1862 [Full Text]